Monocytes in Subjects With Type 1 Diabetes and Chronic Kidney Disease
Key facts
- Where
- Cleveland, United StatesSee the site
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 65 years old?
Source: NCT06694558, who can take part
Where in United States
- Cleveland ClinicCleveland, United StatesTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- The Cleveland Clinic
- Trial code
- NCT06694558
- Record updated
- 8 July 2026
- Original description
This is a cross-sectional study in patients with Type 1 diabetes (TID) and chronic kidney disease (CKD) to test if time in range (TIR) affects the degree of hyperglycemia required for monocyte activation, podocyte injury, and assess if monocyte activation is attenuated by glucagon-like peptide (GLP-1) agonist treatment ex vivo.Read full original descriptionShow less
This is a cross-sectional study in patients with Type 1 diabetes (TID) and chronic kidney disease (CKD) to test if time in range (TIR) affects the degree of hyperglycemia required for monocyte activation, podocyte injury, and assess if monocyte activation is attenuated by glucagon-like peptide (GLP-1) agonist treatment ex vivo.
Inclusion: T1D CKD subjects:; Adults, males or females diagnosed with T1D; Age 18-65 years; Diagnosed with CKD (eGFR 60-90 ml/min/1.73 m2); Diagnosed with albuminuria (UACR 30-500 mg/g); On insulin injections or pump; On CGM; Based on baseline CGM metrics, the investigators will stratify subjects to 2 groups Group A (Lower TIR group): TIR<60%, A1c 7.5-9.5 Group B (Higher TIR group): TIR>70% A1c 5.0-7.0; Controls: T1D subjects without CKD; Adults, males or females diagnosed with T1D; Age 18-65 years; No CKD (eGFR >90 ml/min/1.73 m2); No albuminuria (UACR <30 mg/g); On insulin injections or pump; On CGM; Based on baseline CGM metrics, the investigators will stratify subjects to 2 groups Group A (Lower TIR group): TIR<60%, A1c 7.5-9.5 Group B (Higher TIR group): TIR>70% A1c 5.0-7.0.
Exclusion: On steroids; Reported heavy alcohol use or recreational drug use; Diagnosed with cancer, immunosuppression/autoimmune conditions; Any condition which jeopardizes patient safety or affects monocytes at physician's discretion; Hemoglobin <9; On GLP-1 agonist or DPP4 inhibitor or sodium-glucose co-transporter-2 inhibitors use within 30 days; pregnancy or plans to become pregnant.